Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

Second-generation, highly selective COX-2 inhibitors developed at Merck

Nov. 18, 1997

New cardiotonic candidate studied, rejected at Fujisawa

Nov. 18, 1997

Antiatherosclerotic activity of Roche's benzodiazepine derivative Ro-11-1464 described

Nov. 17, 1997

New renin inhibitor in preclinical testing at JT/Yoshitomi

Nov. 17, 1997

Ribozyme, Chiron initiate product development of RPI-4610

Nov. 14, 1997

Pfizer describes new PDE IV inhibitor for asthma

Nov. 14, 1997

Potent antineoplastic camptothecin derivative identified

Nov. 14, 1997

Conformationally constrained arginal thrombin inhibitors prepared at Lusofarmaco/Guidotti

Nov. 13, 1997

New NHE inhibitor (EMD-85131) shows promise for ischemic heart disease

Nov. 12, 1997

Nonpeptide alphav/beta3 antagonist effective in rabbit model of neointima formation

Nov. 12, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...